Chronic Lymphocytic Leukemia

Single-agent ibrutinib demonstrated an overall response rate of 91%, including a complete response rate of 14%, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Ibrutinib and idelalisib will increase individual out-of-pocket and societal costs of caring for patients with CLL.

In an interview with OncLive, William G. Wierda, MD, PhD, discusses the changing role of chemotherapy in the management of CLL and the integration of novel agents into clinical practice.

Progression on treatment with ibrutinib in patients with chronic lymphocytic leukemia was associated with pretreatment BCL6 abnormalities, acquired mutations in BTK and PLCG2, and complex karyotypes.

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center in Houston, discusses upcoming RESONATE-2 trial results for patients with chronic lymphocytic leukemia (CLL).

The phase III HELIOS study examining ibrutinib in combination with bendamustine and rituximab has been unblinded following the demonstration of a significant extension in progression-free survival in patients with CLL or SLL.

AbbVie has announced plans to acquire the blockbuster BTK inhibitor ibrutinib, through a $21 billion acquisition of Pharmacyclics.

For additional insight on new agents and other emerging CLL therapies, OncLive spoke with Thomas Kipps, MD, PhD, professor of Medicine in the Division of Hematology-Oncology, and Deputy Director for Research at the UC San Diego Moores Cancer Center.

Thomas Kipps, MD, PhD, Division of Hematology-Oncology Deputy Director for Research at the UC San Diego Moores Cancer Center, discusses the mechanisms of ibrutinib and idelalisib for the treatment of chronic lymphocytic leukemia (CLL).

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

ASCO named the vastly improved outlook for patients with chronic lymphocytic leukemia as its inaugural "Cancer Advance of the Year."

The FDA has updated the label for obinutuzumab plus chlorambucil to include data from stage 2 of the phase III CLL11 study, which detailed an unprecedented improvement in progression-free survival compared with rituximab plus chlorambucil as a frontline treatment for patients with chronic lymphocytic leukemia.